RESEARCH ARTICLE

Is routine ophthalmoscopy really necessary in candidemic patients?

Antonio Vena1,2,3,4 *, Patricia Muñoz1,2,3,5 *, Belen Padilla1, Maricela Valerio1, Maria Isabel Sanchez6, Mireia Puig-Asensio7, Jesus Fortun8, Mario Fernandez-Ruiz9, Paloma Merino10, Juan Emilio Losa11, Ana Loza12, Rosa Ana Rivas13, Emilio Bouza1,2,3,5, for the CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI

1 Clinical Microbiology and Infectious Disease Division, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2 Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain, 3 Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain, 4 Clínica Malattie Infettive AOU Santa Maria della Misericordia Piazzale Santa Maria della Misericordia, 15, Udine, Italy, 5 CIBER Enfermedades Respiratorias- CIBERES (CB06/06/0058), Madrid Spain, 6 Hospital Majadahonda, Madrid, Spain, 7 Hospital Universitario Vall D’Hebron, Barcelona, Spain, 8 Hospital Ramón y Cajal, Madrid, Spain, 9 Hospital Universitario 12 de Octubre, Madrid, Spain, 10 Hospital Clínico, Madrid, Spain, 11 Hospital de Alcorcón, Madrid, Spain, 12 Hospital Universitario Virgen de Valme, Sevilla, Spain, 13 Hospital de Galdakano, Bilbao, Spain

¶ Complete membership of the author group can be found in the Acknowledgments section.

Abstract

The purpose of this study was to determine among patients with candidemia the real rate of ophthalmoscopy and the impact of performing ocular assessment on the outcome of the disease. We performed a post hoc analysis of a prospective, multicenter, population-based candidemia surveillance program implemented in Spain during 2010–2011 (CANDIPOP). Ophthalmoscopy was performed in only 168 of the 365 patients with candidemia (46%). Ocular lesions related to candidemia were found in only 13/168 patients (7.7%), of whom 1 reported ocular symptoms (incidence of symptomatic disease in the whole population, 0.27% [1/365]). Ophthalmological findings led to a change in antifungal therapy in only 5.9% of cases (10/168), and performance of the test was not related to a better outcome. Ocular candidiasis was not associated with a worse outcome and progressed favorably in all but 1 evaluable patient, who did not experience vision loss. The low frequency of ophthalmoscopy and ocular involvement and the asymptomatic nature of ocular candidiasis, with a favorable outcome in almost all cases, lead us to reconsider the need for systematic ophthalmoscopy in all candidemic patients.

Introduction

Ocular involvement in patients with candidemia is classically reported as a significant complication with devastating consequences, a high rate of vision loss, and a potentially fulminant course [1–5]. Several guidelines consistently recommend routine ophthalmoscopy in all candidemic patients [6–9]. That is because when eye involvement is detected, antifungal therapy should include azoles or liposomal amphotericin B, occasionally combined with vitrectomy...
and/or intraocular antifungal drugs, and the duration of treatment should be extended for 4–6 weeks [6–9].

Nevertheless, recent series showed a low frequency of symptomatic ocular disease and a favorable clinical outcome in almost all patients with Candida eye involvement who received systemic antifungal treatment [10]. Moreover, the recommendation to perform systematic ophthalmoscopy is based not on the findings of a randomized controlled trial, but rather on the results of old, small-scale studies that do not clearly state clinical benefits [1–5].

Based on data from a recent population-based study of candidemia in Spain (CANDIPOP study), we determined the frequency of ophthalmoscopy and analyzed the impact of the examination on outcome.

**Materials and methods**

**Study setting**

The findings reported here are from a post hoc sub-analysis of the Population Study on Candidemia (CANDIPOP), a prospective, multicenter, population-based candidemia surveillance program implemented in 29 hospitals in Spain. The inclusion criteria, study population, main definitions, microbiological studies, and outcomes have been extensively described elsewhere [11]. Briefly, during the study period local laboratories daily identified patients and reported them to study coordinators, who collected data using a standardized case report form. Data included demographic and clinical characteristics, risk factors for candidemia, antifungal management and source control. Thirty-day follow-up outcome was recorded for each patient. Given the observational nature of the study, patients were managed according to routine clinical care.

Severity of the infection and Pitt bacteremia score were recorded on the day of blood culture sampling [12]. Proven catheter-related candidemia was defined according to current guidelines [13], whereas secondary candidemias required the microbiological documentation of the same Candida species at the origin of infection [11]. When there was no apparent infection at another site, candidemia was classified as primary. An episode of candidemia was defined as persistent when patients had positive follow-up blood cultures performed according to IDSA guidelines [9].

The local institutional review boards of each participating center approved this study, and written informed consent was obtained from each patient before enrollment (IRB of the coordinating center for this study: Comité Ético de Investigación Clínica, Hospital General Universitario Gregorio Marañón).

**Populations**

Systematic dilated ophthalmoscopy was recommended at baseline for all patients included in the study, although only pathological findings suggestive of Candida ocular involvement were recorded in the general CANDIPOP database. To overcome this limitation, we asked the 29 participating hospitals to re-check whether ophthalmoscopy had been performed in patients aged >16 years who had experienced an episode of candidemia. Eleven hospitals complied with our request.

Therefore, we included the 365 episodes of candidemia from the CANDIPOP study for which information was available on whether or not ophthalmoscopy had been performed.

**Collection of ophthalmologic data**

The study coordinators were invited to retrospectively review the results of all ophthalmologic examinations in order to categorize ocular involvement as proven, probable, or possible...
Candida chorioretinitis or endophthalmitis [10]. To be considered proven, ocular candidiasis had to be diagnosed based on the presence of an ocular lesion and on isolation of the microorganism from the vitreous humor by culture or histopathology-based identification. Probable Candida endophthalmitis consisted of vitritis or fluffy lesions with extension into the vitreous humor. Probable Candida chorioretinitis included deep focal white infiltrates in the retina, hemorrhages, Roth spots, or cotton wool spots. In patients with diabetes, hypertension, or concomitant bacteremia, ocular involvement was classified as possible based on previous criteria [10]. Injection of intravitreal antifungal agents or intravitreal corticosteroids was recorded, as was the need for vitrectomy.

The outcome of ocular candidiasis was considered successful when follow-up ophthalmoscopy revealed resolution of the retinal lesion or of active inflammation.

Statistical analysis
Categorical variables are presented as absolute numbers and their relative frequencies. Quantitative variables are presented as means and standard deviation (SD) if normally distributed and as median and interquartile range (IQR) if non-normally distributed. We compared categorical variables between groups using the Pearson chi-square and Fisher exact tests; we compared continuous variables using the Mann-Whitney test or a two-tailed t test.

Risk factors for 30-day mortality were analyzed using the Cox regression model assuming proportional hazards.

One of our main objectives was to analyze the impact of systematic ophthalmoscopy on the outcome of patients with candidemia. Since very early mortality is generally associated with the impossibility to perform an ophthalmoscopy, patients who died within 3 days after withdrawal of blood cultures (12 patients) were excluded from the mortality analysis to rule out potential bias.

Associations are given as odds ratio (OR) with the 95% confidence interval (95% CI). Data were analyzed using SPSS Statistics for Windows, Version 17.0 (SPSS Inc., Chicago, Illinois, USA). Statistical significance was established at $p < 0.05$.

Results
Frequency of ophthalmoscopy and incidence of ocular candidiasis
Ophthalmoscopy was performed in only 168 of the 365 patients with candidemia (46%). Abnormalities suggestive of Candida eye involvement were present in only 13/168 cases (7.7%).

Probable Candida endophthalmitis occurred in 2 patients, whereas probable and possible chorioretinitis were present in 8 and 3 cases, respectively. Interestingly, all patients but 1 (a patient with probable bilateral chorioretinitis who had low visual acuity) were asymptomatic when the diagnosis of ocular candidiasis was established. Accordingly, symptomatic ocular disease due to Candida occurred in 0.27% of the whole candidemic population (1 out of 365 patients) and in 7.6% of the 13 patients with ocular involvement (1 out of 13 patients).

Assessment of performing or not ophthalmoscopy on 30-day mortality
Overall, 102/365 patients (27.9%) died within 30 days of the episode; 12 of these patients died within 3 days of blood sample collection and were, therefore, excluded from the mortality analysis. Univariate analysis of risk factors for 30-day mortality in the 90 remaining patients showed that the factors associated with poor outcome were admission to the ICU, previous renal disease, HIV infection, previous corticosteroid treatment, primary source of infection,
septic shock, higher Pitt score, and need for hemodialysis as a complication of candidemia. The factors associated with a better outcome were admission to a surgical ward, receipt of azoles, and ophthalmoscopy. However, when a multivariate analysis was performed, the independent risk factors for mortality (Table 1) were septic shock at presentation of candidemia, primary candidemia, and a high Pitt score. Performance of ophthalmoscopy did not remain an independent protective factor for 30-day mortality (OR, 0.59; 95% CI, 0.34–1.05; \( p = 0.08 \)).

### Clinical impact and outcome of ocular candidiasis

Antifungal therapy was changed after dilated ophthalmoscopy in 10/168 patients (5.9%). Six patients required a change in the class of antifungal administered, whereas 4 patients were prescribed extended treatment.

The outcome of ocular candidiasis is summarized in Table 2. Overall, information on the evolution of ocular candidiasis was available in 7/13 patients (53.8%), since 5 died and fundoscopy follow-up was not available in the remaining patient. Antifungal treatment was considered successful in 6/7 patients. None of the patients with Candida eye involvement needed intravitreal injection of antifungals or surgery.

As for outcome, although patients with ocular involvement had a higher mortality rate compared to patients without ocular candidiasis, the difference was not statistically significant (30-day mortality rate 38.5% [5/13] vs 18.1% [28/155]; \( p = 0.13 \)).

### Comparison between patients with and without Candida eye involvement

In an attempt to determine whether ophthalmoscopy could be avoided in patients with a low risk of ocular candidiasis, we compared patients with and without ocular candidiasis who had undergone ophthalmoscopy.

As shown in Table 3, patients with ocular candidiasis were significantly younger, had more commonly a history of renal disease [53.8% (7/13) vs 26.5% (41/155), \( p = 0.05 \)] and a higher median Pitt score at presentation of the candidemia [3 vs 1 \( p = 0.01 \)]. Fungemia causing ocular candidiasis was more frequently persistent [61.5% (8/13) vs 26.5% (41/155), \( p = 0.02 \)], was produced by *C. albicans* [76.9% (10/13) vs 47.1% (73/155), \( p = 0.04 \)], spread to other organs [38.5% (5/13) vs 9.7% (15/155), \( p = 0.01 \)], and conditioned more need for hemodialysis [30.8% (4/13) vs 1.9% (3/155), \( p = 0.001 \)]. As for antifungal treatment, patients with ocular candidiasis more commonly received an adequate antifungal therapy within the first 48 hours [100 (13/13) vs 67.7% (105/155), \( p = 0.01 \)], and had a longer length of antifungal therapy (mean days

### Table 1. Multivariate logistic regression analysis of prognostic factors associated with 30-day mortality.

| VARIABLE                               | OR    | 95% CI     | \( p \)-value |
|----------------------------------------|-------|------------|--------------|
| Septic shock                           | 2.55  | 1.03–6.34  | 0.04         |
| Primary candidemia                     | 1.8   | 1.04–3.22  | 0.03         |
| Pitt score                             | 1.20  | 1.05–1.37  | <0.01        |
| Performance of ophthalmoscopy          | 0.59  | 0.34–1.05  | 0.08         |
| Corticosteroids therapy within previous 30 days | 0.58  | 0.33–1.02  | 0.06         |
| Surgical ward                          | 0.51  | 0.25–1.03  | 0.06         |
| HIV/AIDS                               | 0.49  | 0.11–1.8   | 0.26         |
| Mucositis                              | 0.37  | 0.13–1.01  | 0.06         |

https://doi.org/10.1371/journal.pone.0183485.t001
| AGE (y/sex) | Risk factor | Results of ophthalmological examination | Other organs involvement | Time to funduscopic examination | Antifungal therapy before fundoscopy | Treatment | Days between diagnosis and first follow-up fundoscopy | Outcome |
|------------|-------------|---------------------------------------|--------------------------|-------------------------------|----------------------------------|-----------|---------------------------------------------|---------|
| 68/M       | Surgery for colon cancer. Broad-spectrum antibiotics. TPN. C. albicans fungemia | Probable bilateral chorioretinitis | No | 5 days | Fluconazole (No change in AF) | Fluconazole (6 weeks) | 7 days | Complete resolution |
| 55/M       | Intra-abdominal aneurysm repair. Broad-spectrum antibiotics. Systemic corticosteroids. Persistent C. albicans fungemia requiring need for dialysis | Probable bilateral chorioretinitis | No | 5 days | Fluconazole (3 days) | Micafungin IV (4 weeks)* | 8 days | Complete resolution |
| 45/M       | TPN. Broad-spectrum antibiotics. Systemic corticosteroids. Persistent C. albicans fungemia requiring need for dialysis | Probable bilateral chorioretinitis | No | 2 days | Anidulafungin (5 days) | Fluconazole (4 days) | Follow-up not available. | Not evaluable. Patient died |
| 71/M       | Abdominal surgery for colon cancer. TPN. Broad-spectrum antibiotics. Persistent C. albicans fungemia | Possible bilateral chorioretinitis | Spleen involvement | 5 days | Caspofungin (3 days) | Fluconazole (16 days) followed by caspofungin (23 days) | 9 days | Complete resolution |
| 17/F       | Leukemia. Neutropenia. Broad-spectrum antibiotics. Persistent C. guilliermondii fungemia. | Probable bilateral chorioretinitis | Skin | 3 days | Voriconazole (15 days) plus L-AMB (for the first 5 days) | Fluconazole plus micafungin (6 weeks) | 16 days | Initial response. Persistence of ocular lesion in right eye at 2 weeks. |
| 53/M       | Cancer patients (cholangiocarcinoma) receiving systemic chemotherapy. Persistent C. parapsilosis fungemia | Possible bilateral chorioretinitis | No | 3 days | Fluconazole (No change in AF) | Fluconazole (32 days) | 9 days | Complete resolution |
| 62/M       | Tongue cancer managed with chemotherapy. Broad-spectrum antibiotic therapy. TPN. Systemic corticosteroid therapy C. parapsilosis fungemia | Probable bilateral endophthalmitis | No | 3 days | Caspofungin (2 days) | Fluconazole (4 days) | Follow-up not available. | Not evaluable. Patient died |
| 43/F       | Systemic corticosteroids. Broad-spectrum antibiotics. TPN. Persistent C. albicans fungemia requiring need for dialysis | Possible bilateral chorioretinitis | Yes. Septic thrombophlebitis | 16 days | Fluconazole (No change in AF) | Fluconazole (20 days) | Follow-up not available. | Not evaluable |

(Continued)
(22.2 vs 39.6, p = 0.047). No further differences were found between the groups regarding demographics, risk factors, and management of candidemia. In the multivariate analysis (Table 4), the independent risk conditions for eye involvement were need for hemodialysis after candidemia (OR, 19.4; 95% CI, 1.7–218.4) and involvement of organs other than the eye (OR, 5.4; 95% CI, 1.1–25.7).

**Discussion**

Our study shows that, despite the recommendation by several guidelines that systematic ophthalmoscopy should be performed in all patients with candidemia [6–9], as many as 50% of patients never actually underwent ophthalmoscopy. Furthermore, the yield of this examination is low, and ocular infection is uncommon and mostly asymptomatic. Our data also show no independent impact of ophthalmoscopy on the outcome of candidemic patients.

The incidence of ocular candidiasis in patients with candidemia varies from 50% in older studies [14–17] to less than 5% in more recent ones [18, 19]. In the present report, the overall

| AGE (y)/ sex | Risk factor | Results of ophthalmological examination | Other organs involvement | Time to funduscopic examination | Antifungal therapy before fundoscopy | Treatment | Days between diagnosis and first follow-up fundoscopy | Outcome |
|-------------|-------------|----------------------------------------|--------------------------|---------------------------------|------------------------------------|-----------|-----------------------------------------------------|---------|
| 52/M        | Broad-spectrum antibiotics. Brain tumor. *C. albicans* fungemia | Probable chorioretinitis in right eye | No                       | 5 days                           | Fluconazole (No change in AF)       | Fluconazole (5 weeks)               | 12 days               | Complete resolution                               |
| 76/M        | Broad-spectrum antibiotics. Cancer. TPN. Persistent *C. albicans* fungemia requiring need for dialysis | Probable endophthalmitis in right eye and chorioretinitis in left eye | No                       | 6 days                           | Fluconazole (No change in AF)       | Fluconazole (11 days)               | Follow-up not available                | Not evaluable. Patient died |
| 35/F        | Broad-spectrum antibiotics. SLE. Corticosteroids. ARF. Persistent *C. albicans* fungemia | Proven bilateral endophthalmitis | Brain                    | 50 days                          | Fluconazole (2 days)                | L-AMB and 5-flucytosine (8 weeks)  | 12 days               | Ocular lesions persisted during follow-up but no active inflammation was detected |
| 66/M        | Cancer. CRF. Previous antibiotics. Abdominal surgery. *C. albicans* fungemia | Probable chorioretinitis in both eyes | Spleen involvement        | 2 days                           | L-AMB (5 days)                      | Fluconazole (6 weeks)               | Follow-up not available             | Not evaluable |
| 65/M        | Abdominal surgery for cancer. Broad-spectrum antibiotics. TPN. *C. albicans* fungemia | Probable bilateralchiorioretinitis | No                       | 6 days                           | Fluconazole (2 days)                | Caspofungin (14 days)               | Follow-up not available.             | Not evaluable. Patient died |

ARF acute renal failure; AF antifungal therapy; CRF chronic renal failure; L-AMB liposomal amphotericin B; SLE systemic erythematous lupus; TPN total parenteral nutrition.

*Patient number 2 was a renal transplant recipient who developed *C. albicans* septic shock after aortic aneurysm repair. Fungal infection was complicated with acute renal failure needing continuous renal replacement therapy and with ocular candidiasis. Micafungin was administered because of stable levels with hemofiltration, lack of drug-drug interaction and because of its activity on *Candida* biofilm (the patient had a central venous catheter that could not be withdrawn). The outcome of ocular candidiasis was good.

https://doi.org/10.1371/journal.pone.0183485.t002
Table 3. Univariate analysis of risk factors for ocular candidiasis.

| Variable                                | No eye involvement (n = 155) | Eye involvement (n = 13) | p   |
|-----------------------------------------|-----------------------------|--------------------------|-----|
| **Age, years, (mean ± SD)**             | 64.6 ± 14.7                 | 54.5 ± 16.4              | 0.02|
| **Sex, male (%)**                       | 84 (54.2)                   | 10 (76.9)                | 0.14|
| **Hospitalization**                     |                             |                          |     |
| Medical ward                            | 58 (37.4)                   | 2 (15.4)                 | 0.13|
| ICU setting                             | 43 (27.7)                   | 5 (38.5)                 | 0.52|
| Surgical ward                           | 42 (27.1)                   | 5 (38.5)                 | 0.35|
| Emergency department                    | 8 (9.5)                     | 1 (2.5)                  | 0.57|
| Others                                  | 4 (2.6)                     | 0 (0)                    | 1   |
| **Type of infection**                   |                             |                          |     |
| Nosocomial                              | 141 (91.0)                  | 11 (84.6)                | 0.35|
| Community-acquired                      | 13 (8.4)                    | 2 (15.4)                 | 0.32|
| Health-care–associated                  | 1 (0.6)                     | 0 (0)                    | 1   |
| **Time between hospitalization and onset of candidemia** | 22.0 (13–35) | 21.5 (14–34) | 0.65 |
| **Hospitalization within previous 3 months** | 100 (64.5) | 8 (61.5) | 1 |
| **Underlying conditions**               |                             |                          |     |
| Cancer                                  | 67 (43.2)                   | 9 (69.2)                 | 0.08|
| Solid tumor                             | 56 (36.1)                   | 8 (61.5)                 | 0.08|
| Cardiovascular disease                  | 53 (34.2)                   | 5 (38.5)                 | 0.76|
| Renal failure                           | 41 (26.5)                   | 7 (53.8)                 | 0.05|
| Diabetes mellitus                       | 39 (25.2)                   | 3 (23.1)                 | 1   |
| Neurologic disease                      | 35 (22.6)                   | 3 (23.1)                 | 1   |
| Surgery (all types <30 days)            | 24 (15.5)                   | 4 (30.8)                 | 0.23|
| Liver disease                           | 22 (14.2)                   | 1 (7.7)                  | 1   |
| Transplant recipients                   | 15 (9.7)                    | 1 (7.7)                  | 1   |
| Neutropenia                             | 12 (7.7)                    | 2 (15.4)                 | 0.29|
| Leukemia                                | 9 (5.8)                     | 1 (7.7)                  | 0.56|
| Mucositis                               | 8 (5.2)                     | 2 (15.4)                 | 0.17|
| Autoimmune disease                      | 7 (4.5)                     | 1 (7.7)                  | 0.48|
| Lymphoma                                | 2 (1.3)                     | 0 (0)                    | 1   |
| HIV/AIDS                                | 2 (1.3)                     | 0 (0)                    | 1   |
| **Pitt score**                          | 1 (0–2)                     | 3 (0.5–4)                | 0.01|
| **Risk factors**                        |                             |                          |     |
| Antibiotic therapy within previous 30 days | 147 (94.8) | 12 (92.3) | 0.52 |
| Immunosuppressive therapy               | 52 (33.5)                   | 6 (46.2)                 | 0.37|
| Antifungal therapy within previous 30 days | 43 (27.7) | 1 (7.7) | 0.18 |
| Corticosteroids at the time of candidemia | 31 (20.0) | 4 (30.4) | 0.47 |
| **Clinical picture**                    |                             |                          |     |
| Sepsis                                  | 126 (81.3)                  | 9 (69.2)                 | 0.28|
| Severe sepsis                           | 16 (10.3)                   | 3 (23.1)                 | 0.17|
| Septic shock                            | 13 (8.4)                    | 1 (7.7)                  | 0.52|
| **Origin**                              |                             |                          |     |
| Catheter                                | 83 (53.5)                   | 5 (38.5)                 | 0.39|
| Primary                                 | 72 (46.5)                   | 8 (61.5)                 | 0.39|
| Urinary tract                           | 13 (8.4)                    | 0 (0)                    | 0.6 |
| Intra-abdominal                         | 5 (3.2)                     | 0 (0)                    | 1   |
| **Candida species**                     |                             |                          |     |
| C. albicans                             | 73 (47.1)                   | 10 (76.9)                | 0.04|

(Continued)
incidence of ocular candidiasis was 7.7%, which is consistent with that observed by Shah et al. [20], who found a 7.9% frequency of chorioretinitis, with no cases of endophthalmitis. The widespread use of early antifungal therapy and improvements in diagnosis may explain the lower incidence of ocular candidiasis observed in recent years [18, 19, 21].

Nevertheless, recent guidelines recommend performing ophthalmoscopy in all candidemic patients [6–9], stating that “missing and not appropriately treating Candida endophthalmitis

### Table 3. (Continued)

| Variable                                      | No eye involvement (n = 155) | Eye involvement (n = 13) | p    |
|-----------------------------------------------|-----------------------------|-------------------------|------|
| C. parapsilosis                               | 34 (21.9)                   | 2 (15.4)                | 0.73 |
| C. glabrata                                   | 20 (12.9)                   | 0 (0)                   | 0.36 |
| C. tropicalis                                 | 17 (11.0)                   | 0 (0)                   | 0.36 |
| C. krusei                                     | 4 (2.6)                     | 0 (0)                   | 1    |
| Others                                        | 28 (18.1)                   | 1 (7.7)                 | 0.47 |

#### Intravascular catheter at the time of candidemia

|                          | Overall   | Eye (100) | p  |
|--------------------------|-----------|-----------|----|
| Overall                  | 151 (97.4)| 13 (100)  | 1  |
| Central                  | 122 (78.7)| 12 (92.3) | 0.47|
| Peripheral               | 73 (47.1) | 4 (30.8)  | 0.39|

#### Type of catheter

| Type of catheter                              | Overall   | Eye (100) | p  |
|-----------------------------------------------|-----------|-----------|----|
| Subclavian                                    | 40 (25.8) | 5 (38.5)  | 0.33|
| Jugular                                       | 35 (22.6) | 5 (38.5)  | 0.19|
| Peripherally inserted central catheter        | 29 (18.7) | 1 (7.7)   | 0.47|
| Arterial                                      | 20 (12.9) | 3 (23.1)  | 0.39|
| Tunnelle central venous catheter              | 18 (11.6) | 1 (7.7)   | 1   |
| Femoral                                       | 17 (11.0) | 2 (15.4)  | 0.64|

#### Complications due to candidemia

| Complications due to candidemia                | Overall   | Eye (100) | p  |
|-----------------------------------------------|-----------|-----------|----|
| Other organs involvement                      | 15 (9.7)  | 5 (38.5)  | 0.01|
| ICU admission                                 | 9 (5.8)   | 1 (7.7)   | 0.56|
| Dialysis                                      | 3 (1.9)   | 4 (30.8)  | 0.001|

#### Concomitant bacterial infection

| Concomitant bacterial infection               | Overall   | Eye (100) | p  |
|----------------------------------------------|-----------|-----------|----|
| 19 (12.3)                                    | 1 (7.7)   | 1         | 1  |

#### Initiation of antifungal therapy

| Initiation of antifungal therapy             | Overall   | Eye (100) | p  |
|----------------------------------------------|-----------|-----------|----|
| < 24 h since positive BC                     | 59 (38.1) | 6 (46.2)  | 0.56|
| < 48 h since positive BC                     | 105 (67.7)| 13 (100)  | 0.01|
| < 72 h since positive BC                     | 125 (80.6)| 13 (100)  | 0.12|

#### Time to initiation of antifungal therapy since positive BC, median, days (IQR)

| Time to initiation of antifungal therapy since positive BC, median, days (IQR) | Overall   | Eye (100) | p  |
|--------------------------------------------------------------------------------|-----------|-----------|----|
| 2 (1–2)                                                                       | 2         | 2 (1–2)   | 0.43|

#### First antifungal therapy

| First antifungal therapy | Overall   | Eye (100) | p  |
|--------------------------|-----------|-----------|----|
| Azoles                   | 88 (56.5) | 10 (76.9) | 0.24|
| Echinocandins            | 53 (34.2) | 3 (23.1)  | 0.54|
| L-AMB                    | 14 (9.0)  | 0 (0)     | 0.60|

#### Length of antifungal therapy

| Length of antifungal therapy | Overall   | Eye (100) | p  |
|------------------------------|-----------|-----------|----|
| 22.2 ± 14.5                 | 39.6± 36.6| 0.047     |

#### Persistent candidemia

| Persistent candidemia | Overall   | Eye (100) | p  |
|-----------------------|-----------|-----------|----|
| 41 (26.5)             | 8 (61.5)  | 0.02      |

#### Length of antifungal treatment (median, days)

| Length of antifungal treatment (median, days) | Overall   | Eye (100) | p  |
|---------------------------------------------|-----------|-----------|----|
| 3 (1–15)                                    | 2 (1–16)  | 0.94      |

#### Death

| Death                                      | Overall   | Eye (100) | p  |
|--------------------------------------------|-----------|-----------|----|
| 7-day mortality                            | 6 (3.9)   | 0 (0)     | 1  |
| Overall mortality                          | 28 (18.1) | 5 (38.5)  | 0.13|

BC blood culture; ICU intensive care unit; IQR interquartile range; L-AMB liposomal amphotericin B; TPN total parenteral nutrition.

https://doi.org/10.1371/journal.pone.0183485.t003
could have great consequences for the patients” [9]. However, the quality of the evidence supporting this recommendation is low, as it is based on the clinical judgment of the Expert Panel members.

This weakness in the recommendations provided by guidelines is reflected in the wide range of rates of ophthalmoscopy in candidemic patients (53% to 75%) reported in the medical literature [22, 23]. In the same sense, although all patients included in the CANDIPOP study were prospectively followed by infectious disease specialists, we found that in "real life", ophthalmoscopy was performed in less than 50% of the study population. In our fully publicly funded health care system, this low percentage cannot be attributed to cost- or reimbursement-related factors.

As for clinical manifestations, we found only 1 patient with ocular symptoms, ie, an incidence of symptomatic disease of 0.27% in the whole candidemic population. Moreover, ocular candidiasis progressed favorably in all except 1 of our evaluable patients, who was asymptomatic and did not experience vision loss. These findings are consistent with those recently reported by Oude Lahof, who observed visual symptoms in only 3.3% of patients with ocular candidiasis and a favorable outcome in almost all evaluable cases [10]. Older studies reporting ocular candidiasis as a “malignant complication” were performed in an era when medical management of candidemia differed substantially from contemporary care [1–5, 24–26]. Furthermore, a high proportion of patients included in such studies had a history of intravenous drug use [5] that was not observed in our series.

Oude Lahof [10] found a similar mortality rate between patients with and without ocular candidiasis (43.3% vs. 36.5%, $p = 0.31$). We also observed nonsignificant differences ($p = 0.13$), thus indicating that the presence of ocular abnormalities does not predict a poor outcome.

Similarly, although the populations undergoing or not undergoing ophthalmoscopy were likely not identical, we did not observe an impact of routine ophthalmoscopy on clinical outcome. Performance of the examination resulted in a change in antifungal therapy in only 5.6% of the 168 patients. On the contrary, ophthalmoscopy generates an increase in hospital costs ($400 per consultation), is uncomfortable for patients, and carries a small risk of acute angle-closure glaucoma [27].

Since ocular candidiasis progressed favorably in almost all patients and given the lack of data on the clinical impact of longer treatment schedules, we believe that the recommendation of systematic dilated ophthalmoscopy for all candidemic patients should be reassessed. An alternative could be a risk-based approach, in which the examination is limited to symptomatic patients, those who do not respond to treatment, or those more likely to acquire ocular candidiasis.

Regarding this aspect, our findings are consistent with those reported by other investigators [10, 15, 20, 28, 29], who found increased severity of the underlying conditions (cancer, need for hemodialysis after candidemia, and corticosteroids) and exposure to a more virulent

### Table 4. Risk conditions for ocular candidiasis. Multivariate analysis.

| VARIABLES                        | Odds ratio | 95% confidence interval | $p$   |
|----------------------------------|------------|-------------------------|-------|
| Dialysis after candidemia        | 19.4       | 1.7–218.4               | 0.02  |
| Other organs involvement         | 5.4        | 1.1–25.7                | 0.04  |
| Fungemia due to *C. albicans*    | 4.2        | 0.8–20.2                | 0.08  |
| Persistent candidemia            | 3.0        | 0.7–13.7                | 0.15  |
| Initial echinocandin therapy     | 2.6        | 0.4–16.3                | 0.29  |
| Pitt score                       | 1.2        | 0.8–1.6                 | 0.40  |

https://doi.org/10.1371/journal.pone.0183485.t004
infection (C. albicans, persistent fungemia, septic metastasis in other organs) as risk factors for ocular candidiasis.

Our study is subject to a series of limitations. First, the CANDIPOP study was not designed to analyze ocular candidiasis; however, we report the broadest experience to date on ophthalmoscopy in a large population of patients who were prospectively followed by an infectious disease specialist. Second, only 46% of the candidemic patients underwent ophthalmoscopy, with the result that we may have underestimated the involvement of ocular Candida infection; however, no clinical manifestations of ocular candidiasis were observed in the group of patients who did not undergo ophthalmoscopy. Finally, no patients with a history of drug addiction were included in the study.

In conclusion, we provide data from a large series of patients with candidemia showing that ophthalmological assessment is frequently omitted and that the rate of ocular candidiasis is relatively low (7.7%), anecdotally symptomatic, and usually associated with a good outcome. A prospective clinical trial evaluating the real benefits of routinely performed ocular assessment in all candidemic patients to limit the use of such a cumbersome, low-yield examination.

Acknowledgments

We would like to acknowledge GEIH-GEMICOMED, Grupo de Estudio de Infección Hospitalaria-Grupo de Estudio de Micología Médica and REIPI, Red Española de Investigación en Patología Infecciosa and SEIMC, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

Members of the CANDIPOP Project: Belén Padilla, Patricia Muñoz, and Jesús Guinea (Hospital General Universitario Gregorio Marañón, Madrid); José Ramón Paño Pardo, Julio García-Rodríguez, and Carlos García Cerrada (Hospital Universitario La Paz, Madrid); Jesús Fortún, Pilar Martín, and Elia Gómez (Hospital Universitario Ramón y Cajal, Madrid); Pablo Ryan and Carolina Campelo (Hospital Infantil Leonor, Madrid); Ignacio de los Santos Gil and Ventura Buendía (Hospital Universitario La Princesa, Madrid); Beatriz Perez Gorricho and Mercedes Alonso (Hospital Universitario del Niño Jesús, Madrid); Francisca Sanz Sanz and José María Aguado (Hospital Universitario “12 de Octubre,” Madrid); Paloma Merino and Fernando González Romo (Hospital Clínico San Carlos, Madrid); Miguel Gorgolas and Ignacio Gadea (Fundación Jiménez Díaz, Madrid); Juan Emilio Losa and Alberto Delgado-Iribarren (Hospital de Alcorcón, Madrid); Antonio Ramos, Yolanda Romero, and Isabel Sánchez Romero (Hospital Universitario Puerta de Hierro-Majadahonda, Madrid); Oscar Zaragoza and Manuel Cuenca-Estrella (Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid); Jesús Rodríguez-Baño and Ana Isabel Suarez (Hospital Universitario Virgen Macarena, Sevilla); Ana Loza, Ana Isabel Aller García, and Estrella Martín-Mazuelos (Hospital Universitario Virgen de Valme, Sevilla); Maite Ruiz Pérez de Pipaón and José Garnacho (Hospital Universitario Virgen del Rocío, Sevilla); Carlos Ortiz (Hospital Quirón Sagrado Corazón, Sevilla); Mónica Chávez and Fernando L. Maroto (Hospital San Juan de Dios de Aljarafe, Sevilla); Miguel Salvadó and Javier Pemán (Hospital Universitari La Fe, Valencia); José Blanquer and David Navarro (Hospital Clínico Universitario de Valencia); Juan José Camarena and Rafael Zaragoza (Hospital Universitario Dr. Peset, Valencia); Vicente Abril and Concepción Gimeno (Consorcio Hospital General Universitario de Valencia); Silvia Hernández and Guillermo Ezpeleta (Hospital de Basurto, Bilbao); Elena Bereciartua, José L. Hernández Almaraz, and Miguel Montejo (Hospital Universitario de Cruces, Bilbao); Rosa Ana Rivas and Rafael Ayarza (Hospital de Galdakano, Bilbao); Ana Mª Planes, Isabel Ruiz Camps, and Benito Almirante (Hospital Universitario Vall d’Hebron, Barcelona); José Mensa and Manel Almela (Hospital Clínico IDIBAPS, Barcelona); Mercè Gurguí and Ferran Sánchez-Reus (Hospital
Universitario de Sant Pau i Santa Creu, Barcelona); Joaquin Martinez-Montauti and Montserrat Sierra (Hospital de Barcelona, Barcelona); Juan Pablo Horcajada, Luisa Sorli, and Julià Gómez (Hospital del Mar, Barcelona); Amadeu Gené and Mireia Urrea (Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona). Study collaborators: Maricela Valerio, Ana Díaz-Martín, Francesc Puchades, and Alessandra Mularoni.

We would like to express our special thanks to Guillermo Cuervo for helping us with the preparation of the database.

Author Contributions

Conceptualization: Antonio Vena, Patricia Muñoz, Jesus Fortun.

Data curation: Antonio Vena, Patricia Muñoz, Belen Padilla, Maricela Valerio, Maria Isabel Sanchez, Mireia Puig-Asensio, Jesus Fortun, Mario Fernandez-Ruiz, Paloma Merino, Juan Emilio Losa, Ana Loza, Rosa Ana Rivas, Emilio Bouza.

Formal analysis: Antonio Vena, Patricia Muñoz, Belen Padilla, Mireia Puig-Asensio.

Funding acquisition: Antonio Vena.

Investigation: Antonio Vena, Belen Padilla.

Methodology: Antonio Vena.

Writing – original draft: Antonio Vena, Patricia Muñoz.

Writing – review & editing: Antonio Vena, Patricia Muñoz.

References

1. Michelson PE, Rupp R, Efthimiadis B. Endogenous Candida endophthalmitis leading to bilateral corneal perforation. Am J Ophthalmol. 1975; 80(5):800–3. Epub 1975/11/01. PMID: 1081343.

2. Hinzpeter EN, Eisert S, Naumann GO, Utermann D. [The clinical picture of metastatic myotic endophthalmitis (author's transl)]. Klin Monbl Augenheilkd. 1976; 168(3):303–10. Epub 1976/03/01. PMID: 1085840.

3. Barthelemy F, Offret H, Saragossi JJ, Pouliquen Y, Dherny P. [Drug addiction and endophthalmitis due to Candida albicans: diagnostic and therapeutic problems (author's transl)]. J Fr Ophtalmol. 1981; 4 (10):637–46. Epub 1981/01/01. PMID: 6977563.

4. Jt Riddell, Corner GM Kaufman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011; 52(5):648–53. Epub 2011/01/18. https://doi.org/10.1093/cid/ciq204 PMID: 21239843.

5. Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K, et al. Factors determining visual outcome in endogenous Candida endophthalmitis. Retina. 2012; 32(6):1129–34. Epub 2012/02/03. https://doi.org/10.1097/IAE.0b013e31822da3a4 PMID: 22298012.

6. Bow EJ, Evans G, Fuller J, Laverdere M, Rotstein C, Rennie R, et al. Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol. 2010; 21(4):e122–50. Epub 2010/01/01. PMID: 22132006; PubMed Central PMCID: PMC3009581.

7. Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glockner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011; 54(4):279–310. Epub 2011/06/16. https://doi.org/10.1111/j.1439-0507.2011.02040.x PMID: 21672038.

8. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7:19–37. Epub 2013/01/04. https://doi.org/10.1111/j.1469-0691.12039 PMID: 23137135.

9. Pappas PG, Kaufman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62(4):e1–50. Epub 2015/12/19. https://doi.org/10.1093/cid/civ933 PMID: 26679628; PubMed Central PMCID: PMC4725385.
10. Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011; 53(3):262–8. Epub 2011/07/19. https://doi.org/10.1093/cid/cir355 PMID: 21765074.

11. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014; 20(4):O245–54. Epub 2013/10/16. https://doi.org/10.1111/1469-0691.12380 PMID: 24125548.

12. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39(1):31–7. Epub 2004/05/10. https://doi.org/10.1086/420816 PMID: 15206050.

13. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(1):1–45. Epub 2009/06/06. https://doi.org/10.1086/599376 PMID: 19489710; PubMed Central PMCID: PMC4039170.

14. McDonnell PJ, McDonnell JM, Brown RH, Green WR. Ocular involvement in patients with fungal infections. Ophthalmology. 1985; 92(5):706–9. Epub 1985/05/01. PMID: 3874382.

15. Donahue SP, Greven CM, Zuraveff JJ, Eller AW, Nguyen MH, Peacock JE Jr., et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology. 1994; 101(7):1302–9. Epub 1994/07/01. PMID: 8035995.

16. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989; 149(10):2226–8. Epub 1989/10/01. PMID: 2802888.

17. Griffin JR, Pettit TH, Fishman LS, Foos RY. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch Ophthalmol. 1973; 89(6):450–6. Epub 1973/06/01. PMID: 4706441.

18. Dozier CC, Tarantola RM, Jiramongkolchai K, Donahue SP. Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation. Ophthalmology. 2011; 118(6):1671–6. Epub 2011/05/10. https://doi.org/10.1016/j.jophtha.2011.01.038 PMID: 21550121.

19. Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc. 2002; 100:67–70; discussion 1. Epub 2003/01/28. PMID: 12545679; PubMed Central PMCID: PMC1358948.

20. Shah CP, McKey J, Spirt MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008; 92(4):466–8. Epub 2008/03/29. https://doi.org/10.1136/bjo.2007.133405 PMID: 18369061.

21. Salam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther. 2006; 4(4):675–85. Epub 2006/10/03. https://doi.org/10.1586/14787210.4.4.675 PMID: 17009945.

22. Antworth A, Collins CD, Kunapuli A, Klein K, Carver P, Gandhi T, et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy. 2013; 33(2):137–43. Epub 2013/01/29. https://doi.org/10.1002/phar.1186 PMID: 23352883.

23. Takesue Y, Ueda T, Mikamo H, Oda S, Takakura S, Kitagawa Y, et al. Management bundles for candidaemia: the impact of compliance on clinical outcomes. J Antimicrob Chemother. 2015; 70(2):587–93. Epub 2014/10/19. https://doi.org/10.1093/jac/dku414 PMID: 25326087; PubMed Central PMCID: PMC4291239.

24. Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthal Surg Lasers. 1996; 27(12):1012–8. Epub 1996/12/01. PMID: 8976520.

25. Okhravi N, Adamson P, Mant R, Matheson MM, Midgley G, Towler HM, et al. Polymerase chain reaction and restriction fragment length polymorphism mediated detection and speciation of Candida spp causing intraocular infection. Invest Ophthalmol Vis Sci. 1998; 39(6):859–66. Epub 1998/05/14. PMID: 9579465.

26. Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore). 2003; 82(2):97–105. Epub 2003/03/18. PMID: 12640186.

27. Vinikoor MJ, Zaghiby J, Cohen KL, Tucker JD. Do all candidemic patients need an ophthalmic examination? Int J Infect Dis. 2013; 17(3):e146–8. Epub 2013/02/02. https://doi.org/10.1016/j.ijid.2012.12.014 PMID: 23369606.

28. Munoz P, Vena A, Padilla B, Valerio M, Sanchez MI, Puig-Asensio M, et al. No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins. Diagn Microbiol Infect Dis. 2017; 88(2):141–4. Epub 2017/04/04. https://doi.org/10.1016/j.diagmicrobio.2017.02.014 PMID: 28366609.
29. Blennow O, Tallstedt L, Hedquist B, Gardlund B. Duration of treatment for candidemia and risk for late-onset ocular candidiasis. Infection. 2013; 41(1):129–34. Epub 2012/12/06. https://doi.org/10.1007/s15010-012-0369-8 PMID: 23212461.